Sarcoma  >>  Cyramza (ramucirumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cyramza (ramucirumab) / Eli Lilly
NCT04145700 / 2018-004243-23: CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Terminated
1/2
23
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Gemcitabine, Docetaxel
Eli Lilly and Company
Synovial Sarcoma
02/23
02/23

Download Options